Navigation Links
Jazz Pharmaceuticals to Present at Investor Conferences
Date:5/16/2008

PALO ALTO, Calif., May 16 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Robert M. Myers, the company's President, will provide a corporate presentation at two upcoming investor conferences.

Mr. Myers will speak at the UBS Global Specialty and Generic Pharmaceuticals Conference in London at 9:30 a.m. BST (4:30 a.m. EDT) on Wednesday, May 28, 2008.

On Thursday, May 29, 2008 Mr. Myers will present at the FBR Capital Markets Spring Investor Conference in New York City at 8:15 a.m. EDT.

A live webcast of the presentations may be accessed by visiting the Investors section of the Jazz Pharmaceuticals website at http://www.JazzPharmaceuticals.com. A replay will be available on Jazz Pharmaceuticals' website for two weeks following each presentation.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
2. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
3. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
4. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
7. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
9. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
10. Vion Pharmaceuticals to Appeal Nasdaq Delisting
11. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: